Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
- McFarland Clinic - Boone — Boone, Iowa
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
- McFarland Clinic - Boone — Boone, Iowa
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
- Physicians' Clinic of Iowa PC — Cedar Rapids, Iowa
- Mercy Hospital — Cedar Rapids, Iowa
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- Saint Luke's Hospital — Cedar Rapids, Iowa
- Mercy Cancer Center-West Lakes — Clive, Iowa
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Iowa: - Medical Oncology and Hematology Associates-West Des Moines — Clive, Iowa
- Mercy Cancer Center-West Lakes — Clive, Iowa
- Alegent Health Mercy Hospital — Council Bluffs, Iowa
- Greater Regional Medical Center — Creston, Iowa
- Iowa Methodist Medical Center — Des Moines, Iowa
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
- Saint Luke's Hospital — Cedar Rapids, Iowa
- Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
- Mercy Hospital — Cedar Rapids, Iowa
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Iowa: - Mission Cancer and Blood — Des Moines, Iowa
Phase 3 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…
Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Iowa: - Clinical Trial Site — Ames, Iowa
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06618287
Sites in Iowa: - Local Institution - 0065 — Iowa City, Iowa
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1 Recruiting Industry
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH) within each cohort.
Sponsor: TerSera Therapeutics LLC
NCT ID: NCT07310420
Sites in Iowa: - Mission Cancer and Blood — Des Moines, Iowa
Phase 1 Recruiting Industry
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body bes…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05208762
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1 Recruiting Industry
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to e…
Sponsor: Aktis Oncology, Inc.
NCT ID: NCT07020117
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1 Recruiting Industry
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic …
Sponsor: Orano Med Theranostics, SAS
NCT ID: NCT05283330
Sites in Iowa: - University of Iowa Health Care — Iowa City, Iowa
Phase 4 Recruiting Academic/Other
This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants wil…
Sponsor: University of Illinois at Chicago
NCT ID: NCT06169371
Sites in Iowa: - Iowa Holden Comprehensive Cancer Center — Iowa City, Iowa
Phase 4 Recruiting Academic/Other
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be init…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT03096418
Sites in Iowa: - University of Iowa Health Care/Holden Comprehensive Cancer Center — Iowa City, Iowa